Glutathione S-transferases T1 null genotype is associated with susceptibility to aristolochic acid nephropathy

International Urology and Nephrology

Volumn 44, Issue 1, 2012, Pages 301-307

  Chen, Bicheng ^a   Bai, Yongheng ^a   Sun, Mei ^a   Ni, Xiaojie ^a   Yang, Yunxiu ^a   Yang, Yirong ^a   Zheng, Shaoling ^a   Xu, Feifei ^a   Dai, Shengchuan ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Aristolochic acid nephropathy (AAN); Glutathione S transferases T1 (GSTT1); Polymorphism

Indexed keywords

CREATININE; CYTOCHROME P450 1A1; DNA; GLUTATHIONE TRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; GLYCOPROTEIN P; HERBACEOUS AGENT; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ARISTOLOCHIC ACID NEPHROPATHY; ARTICLE; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; ASIAN; CHEMICALLY INDUCED DISORDER; CHINA; CONFIDENCE INTERVAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK; STATISTICAL MODEL;

ADULT; AGED; ARISTOLOCHIC ACIDS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CONFIDENCE INTERVALS; CYTOCHROME P-450 CYP1A1; DRUGS, CHINESE HERBAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); ODDS RATIO; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 84861115794     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-0082-z     Document Type: Article

References (31)

1. Vanherweghem JL, Depierreux M, Tielemans C et al (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341(8842):387-391
2. Arlt VM, Stiborova M, Schmeiser HH (2002) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17(4):265-277
3. Cosyns JP (2003) Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf 26(1):33-48
4. Depierreux M, Van Damme B, Vanden Houte Ket al (1994) Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 24(2):172-180
5. Chen W, Chen A, Li Y (2001) The clinical and pathological manifestations of aristolochic acid nephropathy-the report of58 cases. Zhonghua Yi Xue Za Zhi 81(18):1101-1105
6. Tanaka A, Shinkai S, Kasuno K et al (1997) Chinese herbs nephropathy in the Kansai area: a warning report. Nippon Jinzo Gakkai Shi 39(4):438-440
7. Pawlik A, Baskiewicz-Masiuk M, Machalinski B et al (2005) Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with metho-trexate and dexamethasone. Eur J Pharmacol 528(1-3): 27-36
8. Xiao Y, Ge M, Xue X et al (2008) Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int 73(11):1231-1239
9. Radjendirane V, Joseph P, Lee YH et al (1998) Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 273(13): 7382-7389
10. Goekkurt E, Al-Batran SE, Hartmann JT et al (2009) Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27(17):2863-2873
11. Anwar-Mohamed A, Elbekai RH, El-Kadi AO (2009) Regulation ofCYP1A1 by heavy metals and consequences for drug metabolism. Expert Opin Drug Metab Toxicol 5(5):501-521
12. Brinkmann U, Roots I, Eichelbaum M (2001) Pharmaco-genetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 6(16):835-839
13. Board PG (1980) Biochemical genetics of glutathione S2 transferase in man. Am J Hum Genet 33:36-43
14. Stiborova M, Frei E, Arlt VM et al (2009) The role of bio-transformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153(1):5-11
15. Stiborova M, Frei E, Arlt VM et al (2008) Metabolic acti-vation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 658(1-2):55-67
16. Laing C, Hamour S, Sheaff M et al (2006) Chinese herbal uropathy and nephropathy. Lancet 368(9532):338
17. Atsuta Y, Kawase H, Hamajima N et al (2005) Use of duplex PCR-CTPP methods for CYP2E1RsaI/IL-2 T-330G and IL-1B C-31T/TNF-A T-1031C polymorphisms. Mol Diagn 9(2):89-94
18. Fu J, Yang YR, Ni XJ et al (2009) Establishment and pre-liminary application of polymerase chain reaction with confronting two-pair primers for the single nucleotide polymorphisms of metabolic enzymes. Zhonghua Liu Xing Bing Xue Za Zhi 30(1):63-67
19. Hamajima N (2001) PCR-CTPP: a new genotyping tech-nique in the era of genetic epidemiology. Expert Rev Mol Diagn 1(1):119-123
20. Farnsworth NR, Akerele O, Bingel AS et al (1985) Medicinal plants in therapy. Bull World Health Organ 63(6):965-981
21. Vanherweghem LJ (1998) Misuse ofherbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med 4(1):9-13
22. Swinney R, Hsu S, Tomlinson G (2006) Phase I and Phase II enzyme polymorphisms and childhood cancer. J Investig Med 54(6):303-320
23. Brady JM, Cherrington NJ, Hartley DP et al (2002) Tissue distribution and chemical induction of multiple drug resis-tance genes in rats. Drug Metab Dispos 30(7):838-844
24. Kiyohara C, Hirohata T, Inutsuka S (1996) The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 87(1):18-24
25. Lee KM, Kang D, Clapper ML et al (2008) CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. CancerEpidemiol Biomarkers Prev 17(5):1120-1126
26. Grando JP, Kuasne H, Losi-Guembarovski R et al (2009) Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med 9(1):21-28
27. Toncheva DI, Von Ahsen N, Atanasova SY et al (2004) Identification ofNQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol 17(3):384-389
28. Moran JL, Siegel D, Ross D (1999) A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci US A 96(14):8150-8155
29. Chao C, Zhang ZF, Berthiller J et al (2006) NAD(P)H: quinone oxidoreductase 1 (NQO1) Pro187Ser polymor-phism and the risk oflung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15(5): 979-987
30. Jiang ZP, Wang YR, Xu P et al (2008) Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol 103(5): 433-444
31. Wang BL, Zhai HY, Chen BY et al (2004) Clinical rela-tionship between MDR1 gene and gallbladder cancer. He-patobiliary Pancreat Dis Int 3(2):296-299